1,480 Shares in DaVita Inc. (NYSE:DVA) Acquired by CX Institutional

CX Institutional bought a new stake in shares of DaVita Inc. (NYSE:DVA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,480 shares of the company’s stock, valued at approximately $205,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. SG Americas Securities LLC increased its position in DaVita by 196.9% in the 1st quarter. SG Americas Securities LLC now owns 29,733 shares of the company’s stock worth $4,105,000 after purchasing an additional 19,719 shares during the last quarter. Truist Financial Corp lifted its stake in shares of DaVita by 54.4% in the 4th quarter. Truist Financial Corp now owns 26,068 shares of the company’s stock valued at $2,731,000 after purchasing an additional 9,180 shares during the last quarter. Bessemer Group Inc. boosted its holdings in DaVita by 2,335.6% in the first quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock worth $1,483,000 after purchasing an additional 10,300 shares in the last quarter. Forsta AP Fonden increased its position in DaVita by 50.3% during the first quarter. Forsta AP Fonden now owns 23,600 shares of the company’s stock worth $3,258,000 after buying an additional 7,900 shares during the last quarter. Finally, Raymond James & Associates lifted its position in shares of DaVita by 135.2% in the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock worth $3,601,000 after buying an additional 19,759 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

DVA stock traded up $0.47 during midday trading on Friday, hitting $139.35. The stock had a trading volume of 205,756 shares, compared to its average volume of 835,330. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $147.93. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The stock has a 50-day simple moving average of $140.10 and a 200 day simple moving average of $133.08. The firm has a market capitalization of $12.22 billion, a price-to-earnings ratio of 15.78, a P/E/G ratio of 1.05 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 70.82%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $2.08 EPS. As a group, equities research analysts anticipate that DaVita Inc. will post 9.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on DVA. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Truist Financial raised their target price on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, May 15th. Bank of America increased their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday. Finally, Barclays increased their price target on shares of DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a report on Monday, May 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $154.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.